Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

Participants Achieving an Objective Response Rate (Cheson 2007)

Secondary Objectives:

• Progression Free Survival

• Overall Survival

• Response Duration

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Maytansine; Rituximab

Criteria

Inclusion criteria:

• Histological diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL)

• Relapsed or refractory after at least one standard treatment including rituximab

• CD19 and CD20 positive disease

Exclusion criteria:

• No bi-dimensionally measurable lesion by CT scan (defined as presence of at least one tumor mass measuring >1.5 x 1.5 cm)

• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.